tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2023-13-4-84-92tumors-1142Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL NOTESСлучай первично множественного синхронного радиоиндуцированного рака в клинической практикеA case of primary multiple synchronous radiogenic cancer in clinical practiceМеньшиковК. В.MenshikovK.  V.

Константин В. Меньшиков, к. м. н., доцент кафедры онкологии с курсами онкологии и патологической анатомии;

врач-онколог отделения химиотерапии

Уфа

Konstantin V. Menshikov, MD, PhD, Associate Professor of the Department of Oncology with Courses of Oncology and Pathological Anatomy;

Oncologist of the Chemotherapy Department

Ufa

СултанбаевА. В.SultanbaevA.  V.

Александр В. Султанбаев, к. м. н., заведующий отделения противоопухолевой лекарственной терапии

Уфа

Alexandr V. Sultanbaev, MD, PhD, Head of the Department of Anticancer Drug Therapy

Ufa

rkodrb@yandex.ruМусинШ. И.MusinS.  I.

Шамиль И. Мусин, к. м. н., заведующий хирургическим отделением № 4

Уфа

Shamil I. Musin, MD, PhD, Head of the Surgical Department No. 4

Ufa

ИзмайловА. А.IzmailovA.  A.

Адель А. Измайлов, д. м. н., главный врач

Уфа

Adel А. Izmailov, MD, PhD, DSc, Chief Physician

Ufa

МеньшиковаИ. А.MenshikovaI.  A.

Ирина А. Меньшикова, к. м. н., доцент кафедры биологической химии

Уфа

Irina А. Menshikova, MD, PhD, Associate Professor of the Department of Biological Chemistry

Ufa

ЧаловВ. С.ChalovV.  S.

Виталий С. Чалов, заведующий отделением радиотерапии, врач-радиотерапевт

Уфа

Vitaliy S. Chalov, Head of the Radiotherapy Department, Radiotherapist

Ufa

СултанбаеваН. И.SultanbaevaN.  I.

Надежда И. Султанбаева, врач-онколог отделения противоопухолевой лекарственной терапии № 1

Уфа

Nadegda I. Sultanbaeva, Oncologist, Department of Antitumor Drug Therapy No. 1

Ufa

ЛипатовД. О.LipatovD.  O.

Данила О. Липатов, студент лечебного факультета

Уфа

Danila О. Lipatov, Medical Student

Ufa

ГАУЗ «Республиканский клинический онкологический диспансер» Минздрава Республики Башкортостан; ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава РоссииРоссияRepublican Clinical Oncological Dispensary; Bashkir State Medical UniversityRussian FederationГАУЗ «Республиканский клинический онкологический диспансер» Минздрава Республики БашкортостанРоссияRepublican Clinical Oncological DispensaryRussian FederationФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава РоссииРоссияBashkir State Medical UniversityRussian FederationЦентр ядерной медицины «ПЭТ-Технолоджи»РоссияCenter for Nuclear Medicine “PET-Technology”Russian Federation2023130720231348492Copyright © Меньшиков К.В., Султанбаев А.В., Мусин Ш.И., Измайлов А.А., Меньшикова И.А., Чалов В.С., Султанбаева Н.И., Липатов Д.О., 20242024Меньшиков К.В., Султанбаев А.В., Мусин Ш.И., Измайлов А.А., Меньшикова И.А., Чалов В.С., Султанбаева Н.И., Липатов Д.О.Menshikov K.V., Sultanbaev A. ., Musin S.I., Izmailov A.A., Menshikova I.A., Chalov V.S., Sultanbaeva N.I., Lipatov D.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1142

структуре заболеваемости наблюдается рост числа пациентов с вторичными злокачественными новообразованиями. Кроме того, в отдельных подгруппах после радикального лечения рака пожизненный риск развития вторичных злокачественных новообразований может достигать 33%. Вторичные злокачественные новообразования остаются важной причиной смерти пациентов, получивших радикальное лечение по поводу рака. Представленный клинический случай демонстрирует развитие первично-множественных злокачественных новообразований после лучевой терапии и химиотерапии. Пациентка в 39 лет по поводу диффузной крупноклеточной В-клеточной неходжскинской лимфомы прошла радикальный курс лечения. Через 10 лет у пациентки были выявлены радиоиндуцированные первично множественные опухоли: злокачественная миофибросаркома правого желудочка сердца IIIB стадии — G2T3N0M0, рак левой молочной железы IIIA стадии — T3N2M0. Определение тактики лечения для данной категории больных остается особенно сложным.

There is an increase in the number of patients with secondary malignant neoplasms. In addition, in some subgroups after radical cancer treatment, the lifetime risk of developing secondary malignant neoplasms can be as high as 33 %. Secondary malignancies remain an important cause of death in patients who have received radical cancer treatment. The presented clinical case demonstrates the risk of developing primary multiple malignant neoplasms after radiation therapy and chemotherapy. A 39‑year-old patient with diffuse large B-cell non-Hodgkin lymphoma underwent definitive treatment including chemo-and radiotherapy. Ten years later, the patient developed the induced multiple malignant tumors: a malignant neoplasm of the heart — myofibrosarcoma of the right ventricle with invasion of the anterior wall of the right ventricle Stage IIIB G2T3N0M0, left breast cancer Stage IIIA T3N2M0. The choice of treatment tactics for this category of patients remains particularly difficult.

неходжкинская лимфомамиофибросаркомарадиоиндуцированные новообразованиярак молочной железыnon-Hodgkin lymphomamyofibrosarcomaradiogenic neoplasmsbreast cancerReferencesLord, C. J. ; Ashworth, A. The DNA damage response and cancer therapy. Nature 2012, 481, 287–294.Lord, C. J. ; Ashworth, A. The DNA damage response and cancer therapy. Nature 2012, 481, 287–294.Valerie, K. ; Povirk, L. F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003, 22, 5792–5812.Valerie, K. ; Povirk, L. F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003, 22, 5792–5812.Jaco, I. ; Muñoz, P. ; Goytisolo, F. ; Wesoly, J. ; Bailey, S. ; Taccioli, G. ; Blasco, M. A. Role of mammalian Rad54 in telomere length maintenance. Mol. Cell Biol. 2003, 23, 5572–5580.Jaco, I. ; Muñoz, P. ; Goytisolo, F. ; Wesoly, J. ; Bailey, S. ; Taccioli, G. ; Blasco, M. A. Role of mammalian Rad54 in telomere length maintenance. Mol. Cell Biol. 2003, 23, 5572–5580.Salzano, A. ; Kochiashvili, N. ; Nergadze, S. G. ; Khoriauli, L. ; Smirnova, A. ; Ruiz-Herrera, A. ; Mondello, C. ; Giulotto, E. Enhanced gene amplification in human cells knocked down for DNA-Kcs. DNA Repair 2009, 8, 19–28.Salzano, A. ; Kochiashvili, N. ; Nergadze, S. G. ; Khoriauli, L. ; Smirnova, A. ; Ruiz-Herrera, A. ; Mondello, C. ; Giulotto, E. Enhanced gene amplification in human cells knocked down for DNA-Kcs. DNA Repair 2009, 8, 19–28.Ruiz-Herrera, A. ; Smirnova, A. ; Khouriauli, L. ; Nergadze, S. G. ; Mondello, C. ; Giulotto, E. Gene amplification in human cells knocked down for RAD54. Genome Integr. 2011, 2, doi: 10.1186/2041-9414-2-5.Ruiz-Herrera, A. ; Smirnova, A. ; Khouriauli, L. ; Nergadze, S. G. ; Mondello, C. ; Giulotto, E. Gene amplification in human cells knocked down for RAD54. Genome Integr. 2011, 2, doi: 10.1186/2041-9414-2-5.Keeney, S. ; Giroux, C. N. ; Kleckner, N. Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. Cell 1997, 88, 375–384.Keeney, S. ; Giroux, C. N. ; Kleckner, N. Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. Cell 1997, 88, 375–384.Roeder, G. S. Meiotic chromosomes : It takes two to tango. Genes Dev. 1997, 11, 2600–2621.Roeder, G. S. Meiotic chromosomes : It takes two to tango. Genes Dev. 1997, 11, 2600–2621.Moens, P. B. ; Kolas, N. K. ; Tarsounas, M. ; Marcon, E. ; Cohen, P. E. ; Spyropoulos, B. The time course and chromosomal localization of recombination-related proteins at meiosis in the mouse are compatible with models that can resolve the early DNA-DNA interactions without reciprocal recombination. J. Cell Sci. 2002, 115, 1611–1622.Moens, P. B. ; Kolas, N. K. ; Tarsounas, M. ; Marcon, E. ; Cohen, P. E. ; Spyropoulos, B. The time course and chromosomal localization of recombination-related proteins at meiosis in the mouse are compatible with models that can resolve the early DNA-DNA interactions without reciprocal recombination. J. Cell Sci. 2002, 115, 1611–1622.Baker, S. M. ; Plug, A. W. ; Prolla, T. A. ; Bronner, C. E. ; Harris, A. C. ; Yao, X. ; Christie, D. M. ; Monell, C. ; Arnheim, N. ; Bradley, A. ; et al. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat. Genet. 1996, 13, 336–342.Baker, S. M. ; Plug, A. W. ; Prolla, T. A. ; Bronner, C. E. ; Harris, A. C. ; Yao, X. ; Christie, D. M. ; Monell, C. ; Arnheim, N. ; Bradley, A. ; et al. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat. Genet. 1996, 13, 336–342.Turner, J. M. ; Aprelikova, O. ; Xu, X. ; Wang, R. ; Kim, S. ; Chandramouli, G. V. ; Barrett, J. C. ; Burgoyne, P. S. ; Deng, C. X. BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr. Biol. 2004, 14, 2135–2142.Turner, J. M. ; Aprelikova, O. ; Xu, X. ; Wang, R. ; Kim, S. ; Chandramouli, G. V. ; Barrett, J. C. ; Burgoyne, P. S. ; Deng, C. X. BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr. Biol. 2004, 14, 2135–2142.Wallace, W. H. ; Thomson, A. B. ; Kelsey, T. W. The radiosensitivity of the human oocyte. Hum. Reprod. 2003, 18, 117–121.Wallace, W. H. ; Thomson, A. B. ; Kelsey, T. W. The radiosensitivity of the human oocyte. Hum. Reprod. 2003, 18, 117–121.Wallace, W. H. ; Thomson, A. B. ; Saran, F. ; Kelsey, T. W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 738–744.Wallace, W. H. ; Thomson, A. B. ; Saran, F. ; Kelsey, T. W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 738–744.Hodgson DC : Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011 : 323–329.Hodgson DC : Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011 : 323–329.Ng AK : Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011, 154 (1) : 23–31.Ng AK : Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011, 154 (1) : 23–31.Elkin EB, Klem ML, Gonzales AM, et al : Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin’s lymphoma : a multi-institutional, matched cohort study. J Clin Oncol 2011, 29 (18) : 2466–2473.Elkin EB, Klem ML, Gonzales AM, et al : Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin’s lymphoma : a multi-institutional, matched cohort study. J Clin Oncol 2011, 29 (18) : 2466–2473.Baker, T. G. Comparative aspects of the effects of radiation during oogenesis. Mutat. Res. 1971, 11, 9±22.Baker, T. G. Comparative aspects of the effects of radiation during oogenesis. Mutat. Res. 1971, 11, 9±22.Donin N, Filson C, Drakaski A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016 ; 122 : 3075–3086.Donin N, Filson C, Drakaski A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016 ; 122 : 3075–3086.Saletta F, Seng M and Lau L. Advances in pediatric cancer treatment. Transl Pediatr 3 (2) : 156–82. 4. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014 ; 64 : 83–103.Saletta F, Seng M and Lau L. Advances in pediatric cancer treatment. Transl Pediatr 3 (2) : 156–82. 4. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014 ; 64 : 83–103.Institute NC. Childhood Cancer by site incidence, survival and mortality 2019, April, https://seer.cancer.gov/csr/1975_2016/results_merged/sect_28_childhood_cancer.pdf.Institute NC. Childhood Cancer by site incidence, survival and mortality 2019, April, https://seer.cancer.gov/csr/1975_2016/results_merged/sect_28_childhood_cancer.pdf.Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer : a summary from the childhood cancer survivor study. J Clin Oncol 2009 ; 27 : 2328–2338.Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer : a summary from the childhood cancer survivor study. J Clin Oncol 2009 ; 27 : 2328–2338.Lee JS, Dubois SG, Coccia PF, et al. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer 2016 ; 122 : 116–123.Lee JS, Dubois SG, Coccia PF, et al. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer 2016 ; 122 : 116–123.Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD : National Cancer Institute ; 2015.Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD : National Cancer Institute ; 2015.Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002 ; 94 : 182–192.Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002 ; 94 : 182–192.Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr. Second cancers following non-Hodgkin’s lymphoma. Cancer. 1991 ; 67 : 2002–2009.Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr. Second cancers following non-Hodgkin’s lymphoma. Cancer. 1991 ; 67 : 2002–2009.Curtis RE, Freedman DM, Ron E, et al. New Malignancies Among Cancer Survivors : SEER Cancer Registries, 1973–2000. Bethesda, MD : National Cancer Institute ; 2006. NIH Pub. No. 05–5302.Curtis RE, Freedman DM, Ron E, et al. New Malignancies Among Cancer Survivors : SEER Cancer Registries, 1973–2000. Bethesda, MD : National Cancer Institute ; 2006. NIH Pub. No. 05–5302.Важенин А. В., Шаназаров Н. А., Шунько Е. Л. Некоторые закономерности развития радиоиндуцированных метахронных опухолей. Вестник рентгенологии и радиологии № 6, 2015. С 30–35.Важенин А. В., Шаназаров Н. А., Шунько Е. Л. Некоторые закономерности развития радиоиндуцированных метахронных опухолей. Вестник рентгенологии и радиологии № 6, 2015. С 30–35.Bertin F, Deluche E, Tricard J, Piccardo A, Denes E. First case of sternum replacement with a bioceramic prosthesis after radio-induced sarcoma. Curr Oncol. 2018 Aug ; 25 (4) : e351-e353. doi: 10.3747/co.25.4020. Epub 2018 Aug 14. PMID : 30111981 ; PMCID : PMC6092061.Bertin F, Deluche E, Tricard J, Piccardo A, Denes E. First case of sternum replacement with a bioceramic prosthesis after radio-induced sarcoma. Curr Oncol. 2018 Aug ; 25 (4) : e351-e353. doi: 10.3747/co.25.4020. Epub 2018 Aug 14. PMID : 30111981 ; PMCID : PMC6092061.Majdoubi A, Serji B, Harroudi TE. Angiosarcome mammaire radio-induit : à propos d’un cas [Radiation-induced breast angiosarcoma : about a case]. Pan Afr Med J. 2020 May 21 ; 36 : 29. French. doi: 10.11604/pamj.2020.36.29.21599. PMID : 32774606 ; PMCID : PMC7388625.Majdoubi A, Serji B, Harroudi TE. Angiosarcome mammaire radio-induit : à propos d’un cas [Radiation-induced breast angiosarcoma : about a case]. Pan Afr Med J. 2020 May 21 ; 36 : 29. French. doi: 10.11604/pamj.2020.36.29.21599. PMID : 32774606 ; PMCID : PMC7388625.Меньшиков К. В., Пушкарев А. В., Султанбаев А. В., Пушкарев В. А., Шарифгалиев И. А. Радиоиндуцированная ангиосаркома влагалища : клинический случай. Креативная хирургия и онкология. 2020 ; 10 (2) : 143–148. https://doi.org/10.24060/2076-3093-2020-10-2-143-148.Меньшиков К. В., Пушкарев А. В., Султанбаев А. В., Пушкарев В. А., Шарифгалиев И. А. Радиоиндуцированная ангиосаркома влагалища : клинический случай. Креативная хирургия и онкология. 2020 ; 10 (2) : 143–148. https://doi.org/10.24060/2076-3093-2020-10-2-143-148.Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease : a population-based evaluation over 25 years. J Clin Oncol. 2002 ; 20 : 3484–94. DOI: 10.1200/JCO. 2002.09.038.Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease : a population-based evaluation over 25 years. J Clin Oncol. 2002 ; 20 : 3484–94. DOI: 10.1200/JCO. 2002.09.038.Огнерубов Н. А., Антипова Т. С. Радиационно-индуцированная саркома мягких тканей шеи после лучевой терапии лимфомы Ходжкина. Клиническое наблюдение. Современная Онкология. 2022 ; 24 (3) : 325–330. DOI: 10.26442/18151434.2022.3.201904.Огнерубов Н. А., Антипова Т. С. Радиационно-индуцированная саркома мягких тканей шеи после лучевой терапии лимфомы Ходжкина. Клиническое наблюдение. Современная Онкология. 2022 ; 24 (3) : 325–330. DOI: 10.26442/18151434.2022.3.201904.van Eggermond AM, Schaapveld M, Lugtenburg PJ. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014 ; 124 (3) : 319–27. DOI: 10.1182/blood-2013-10-532184.van Eggermond AM, Schaapveld M, Lugtenburg PJ. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014 ; 124 (3) : 319–27. DOI: 10.1182/blood-2013-10-532184.Ng AK, Mauch PM. Late effects of Hodgkin’s disease and its treatment. Cancer J. 2009 ; 15 : 164–8. DOI: 10.1097/PPO.0b013e31819e30d7.Ng AK, Mauch PM. Late effects of Hodgkin’s disease and its treatment. Cancer J. 2009 ; 15 : 164–8. DOI: 10.1097/PPO.0b013e31819e30d7.Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin’s disease : a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988 ; 6 (2) : 239–252.Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin’s disease : a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988 ; 6 (2) : 239–252.Eghbali H, Raemaekers J, Carde P ; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol Suppl. 2005 ; (66) : 135–140.Eghbali H, Raemaekers J, Carde P ; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol Suppl. 2005 ; (66) : 135–140.Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al ; European Organisation for Research and Treatment of Cancer. The achievements of the EORTC Lymphoma Group. Eur J Cancer. 2002 ; 38 (suppl 4) : S107-S113.Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al ; European Organisation for Research and Treatment of Cancer. The achievements of the EORTC Lymphoma Group. Eur J Cancer. 2002 ; 38 (suppl 4) : S107-S113.Somers R, Tubiana M, Henry-Amar M. EORTC Lymphoma Cooperative Group studies in clinical stage I–II Hodgkin’s disease 1963–1987. Recent Results Cancer Res. 1989 ; 117 : 175–181.Somers R, Tubiana M, Henry-Amar M. EORTC Lymphoma Cooperative Group studies in clinical stage I–II Hodgkin’s disease 1963–1987. Recent Results Cancer Res. 1989 ; 117 : 175–181.Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials : 1964–1987. Blood. 1989 ; 73 (1) : 47–56.Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials : 1964–1987. Blood. 1989 ; 73 (1) : 47–56.van Eggermond AM, Schaapveld M, Lugtenburg PJ, Krol AD, de Boer JP, Zijlstra JM, Raemaekers JM, Kremer LC, Roesink JM, Louwman MW, Aleman BM, van Leeuwen FE. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014 Jul 17 ; 124 (3) : 319–27 ; quiz 466. doi: 10.1182/blood-2013-10-532184. Epub 2014 Apr 16. PMID : 24740811.van Eggermond AM, Schaapveld M, Lugtenburg PJ, Krol AD, de Boer JP, Zijlstra JM, Raemaekers JM, Kremer LC, Roesink JM, Louwman MW, Aleman BM, van Leeuwen FE. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014 Jul 17 ; 124 (3) : 319–27 ; quiz 466. doi: 10.1182/blood-2013-10-532184. Epub 2014 Apr 16. PMID : 24740811.Cahan WG, Woodard HQ, Higinbotham NL, et al. Sarcoma in irradiated bone. Report of eleven cases. Cancer. 1948 : 3–29. DOI: 10.1002/1097-0142(194805) 1 : 1<3 : : AID-CNCR2820010103>3.0. CO ; 2–7.Cahan WG, Woodard HQ, Higinbotham NL, et al. Sarcoma in irradiated bone. Report of eleven cases. Cancer. 1948 : 3–29. DOI: 10.1002/1097-0142(194805) 1 : 1<3 : : AID-CNCR2820010103>3.0. CO ; 2–7.Hall EJ, Wuu CS. Radiation-induced second cancers : the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003 ; 56 : 83–8. DOI: 10.1016/S0360–3016 (03) 00073–7.Hall EJ, Wuu CS. Radiation-induced second cancers : the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003 ; 56 : 83–8. DOI: 10.1016/S0360–3016 (03) 00073–7.

The authors declare that there are no conflicts of interest present.